Table 3 Hemodynamic evaluations and CRRT settings during study

Number of hemodynamic evaluations

1237

Number of hemodynamic evaluations per patient

33 [19–41]

Study duration (h)

121 [60–147]

Norepinephrine vasopressor dose (µg kg⁻¹ min⁻¹)

0.29 [0.08–0.81]

Vasopressor norepinephrine administration (%)

1042 (85%)

Dobutamine administration (%)

91 (7%)

Arterial lactate (mmol L⁻¹)

1.8 [1.4–2.9]

Heart rate (min⁻¹)

94 [78–110]

MAP (mmHg)

73 [64–81]

CVP (mmHg)

7 [4–10]

CI_TD (L min⁻¹ m⁻²)

3.0 [2.5–3.5]

CI_PC (L min⁻¹ m⁻²)

2.9 [2.4–3.5]

ISVR (dynes s cm⁻⁵)

1780 [1507–2095]

EVLWI (mL kg⁻¹ PBW)

10.5 [8.7–13.3]

PVPI

2.1 [1.8–2.5]

GEDVI (mL m⁻²)

652 [582–811]

GEF (%)

20 [16–23]

PPV (%)

9 [5–15]

SVV (%)

11 [7–18]

Ea_dyn

0.8 [0.7–1.0]

Preload-dependence assessed by postural test

490 (41%)

Type of CRRT

 CVVH

1072 (87%)

 CVVHD

165 (13%)

Ultrafiltration rate (mL kg⁻¹ h⁻¹)^a

27 [24–31]

Dialysate rate (mL kg⁻¹ h⁻¹)^b

25 [23–27]

CRRT blood flow (mL min⁻¹)

250 [200–250]

Net ultrafiltration rate (mL kg⁻¹ h⁻¹)

1.4 [0–2.9]

Ultrafiltrate/dialysate temperature (°C)

38 [37–39]

CRRT circuit anticoagulation

 Heparin

946 (77%)

 Citrate

165 (13%)

 None

126 (10%)